Partner Roger Strode was quoted in a Chicago Tribune article, “Hospira Stock Soars as Pfizer Says it will Buy for $15.23 Billion,” on February 5, 2015. The article discussed details surrounding pharmaceutical giant Pfizer’s plans to buy Illinois drug maker Hospira. Strode was quoted saying, “The shareholders of Hospira are going to be really well off. Hospira’s stock has zoomed already. It’s a huge benefit to them.”
Strode also touched on the outlook for mergers and acquisitions in the pharmaceutical industry and said, “Pharma has been very robust. A lot of companies have done well and they’re sitting on a lot of cash. We’re still in the middle of a bull market.”
Strode also touched on the outlook for mergers and acquisitions in the pharmaceutical industry and said, “Pharma has been very robust. A lot of companies have done well and they’re sitting on a lot of cash. We’re still in the middle of a bull market.”
People
Related News
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."
July 18, 2025
In the News
Aaron Maguregui Highlights Potential Compliance Concerns in Pre-Tax Wellness Claims
Foley & Lardner LLP partner Aaron Maguregui commented in The New York Times article, "Hot Dogs for Insomnia? A Kennedy Aide's Start-Up Can Get You a Tax Break," sharing insight on the growing use of medical necessity letters to support tax-advantaged purchases of wellness products.